

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)



(10) International Publication Number
WO 2021/202731 A1

(51) International Patent Classification:

A61K 31/18 (2006.01) A61P 1/04 (2006.01)
A61K 31/4155 (2006.01) C07D 231/14 (2006.01)
A61K 31/498 (2006.01) C07D 237/00 (2006.01)

(21) International Application Number:

PCT/US2021/025171

(22) International Filing Date:

31 March 2021 (31.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/002,747 31 March 2020 (31.03.2020) US

(71) Applicant: **CHEMOCENTRYX, INC.** [US/US]; 850 Maude Avenue, Mountain View, CA 94043 (US).

(72) Inventors: **CAMPBELL, James**; 2433 Downing Avenue, San Jose, CA 95128 (US). **CHARO, Israel**; 850 Maude Avenue, Mountain View, CA 94043 (US). **SCHALL,**

Thomas; 850 Maude Avenue, Mountain View, CA 94043 (US). **SINGH, Rajinder**; 1832 Hillman Avenue, Belmont, CA 94002 (US). **ZENG, Yibin**; 917 Aruba Lane, Foster City, CA 94404 (US). **ZHANG, Penglie**; 1036 Jamaica Street, Foster City, CA 94404 (US).

(74) Agent: **MARSHALL, Ryan L.** et al.; Barnes & Thornburg LLP, 299 S. Main Street, Suite 1825, Salt Lake City, UT 84111-2571 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES




FIG. 1

(57) Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*